Don't fall for the short and distort screen name changing fools who want to cover at $2.
If the JD and AG were serious about this issue, they would force the FDA to fast track approval of the abuse deterrent formations of PTIE, ACUR and DRRX.
Good point! There is more to this story. Someone had to write a letter complaining about the FDA approval. This was likely a competitor, short seller or both who use an advocacy group to avoid any detection of their true motives to gain from bets against this company's stock.
I am not worried. I think it will be alright for now now. The closer we get to launch, the less risk and potential higher reward. The short will try to get the price down but I don't think they will get much at this price level.
I think the shorts are beginning to throw in the towel at these price levels. The DOJ is not going to help them gain from from their borrowed shares.
I don't think the DOJ will get too involved with this issue and the free markets. It will also observe the benefits of the new approved drug and it will decide to let the issue alone. It also does not have enough empirical evidence to overturn the FDA decision. It can't use implied arguments in court, as evidence, to overturn the decision. It will have to prove that ZGNX new formation is causing more people to use drugs. Right now it does not have any facts to support that conclusion.
The best news is there is no news at this juncture. The price seems to be stabilizing at around $3. The shorts don't look like they want to take on much more risk at these price levels.
"Shorts are totally panicking!" I think they shorted this at much lower prices. They should be in a panic, this stock could hit $6 a share anytime now. Drd may also be an author at SA who shorted this stock below $2.5.
Looks like you will need tamper proof in the place you are heading to for spreading false rumors to promote a short and distort scam. Hopefully, they will also ban you from trading stocks.
[Purdue was involved in measures against prescription drug abuse, particularly of Oxycontin. In 2001, Connecticut Attorney General Richard Blumenthal issued a statement urging Purdue to take action regarding abuse of Oxycontin; he did note that, while Purdue seemed sincere, there was little action being taken beyond "cosmetic and symbolic steps." After Purdue announced plans to reformulate the drug, Blumenthal noted that this would take time, and that "Purdue Pharma has a moral, if not legal, obligation to take effective steps now that address addiction and abuse even as it works to reformulate the drug." The company has since implemented a comprehensive program designed to assist in detection of the illegal trafficking and abuse of prescription drugs without compromising patient access to proper pain control.
In May 2007 the company pleaded guilty to misleading the public about Oxycontin's risk of addiction, and agreed to pay $600 million in one of the largest pharmaceutical settlements in U.S. history. Its president, top lawyer, and former chief medical officer pleaded guilty as individuals to misbranding charges, a criminal violation, and agreed to pay a total of $34.5 million in fines. In addition three top executives were charged with a felony and sentenced to 400 hours of community service in drug treatment programs.]
Some AG admit it was not the drug itself that caused the problem but the actions of the company Prudue. Note that Blumenthal also stated that it "would take time." Well, the AGs can't give others the competitive advantage by letting them continue to market painkillers that are not proven to stop abuse while shutting others out of the markets. This is especially true when the new formation will provide a additional benefit and reduced risk to patients.
"Disrupting a free market." We will see exactly if this case takes a precedence over the free markets. The shorts are also increasing their present in this sectors. It also appears that they are trying to put pressure on the FDA decision making process. Chances are they contacted legislators who are clueless about short selling and the free markets. They just allowed a group of short sellers to gain by interfering in the free markets with their negative report.
That negative article will be forgotten by the March 2014 launch. The FDA is not going to prevent this post drug marketing. I also don't see ACUR, DRRX or PTIE stocks blowing up as a result of this article. The markets are not placing to much weigh on it. The shorts just used it to make a days gain off weak retail investors. Some short traders likely staged a take down while they watched their clients accounts for cheap shares to cover.
[OXECTA® is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
OXECTA® Tablets CII have been commercially available from Pfizer, Inc since January 23, 2012. OXECTA®, which utilizes Acura’s AVERSION® Technology, will be sold in bottles of 100 tablets in 5mg and 7.5mg strengths. The FDA is requiring Pfizer to conduct a post approval epidemiological study to assess whether OXECTA® results in a decrease of the consequences of misuse and abuse.]ACUR
There is one IR on the market. ZGNX should be just fine. The FDA may only require it to develop a abuse deterrent formation. It is moving in that direction for most future painkiller approvals but the process is slow and the science is not perfected.